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Outcomes of HIV-positive patients with end-stage 
kidney disease (ESKD) in the era prior to antiretroviral 
therapy (ART) were dismal.[1] In the USA before 1995, 
when ART was not freely available, median survival 
of HIV-positive patients on chronic haemodialysis 
ranged from 1.4 to 12 months.[2] After 1995, as access to effective ART 
improved, studies began to show progressive improvements in survival 
in HIV-positive patients receiving chronic haemodialysis, but survival 
was still significantly lower than in their HIV-negative counterparts.[3,4] 
In 2006, French researchers showed that the 2-year survival of HIV-
positive patients on haemodialysis with access to ART was comparable 
(89%) to a cohort of HIV-negative patients.[5] Survival rates of black 
HIV-positive patients with ESKD in sub-Saharan Africa are unknown.
ART became freely available in the state health sector in South 
Africa (SA) in 2004, with access expanding dramatically so that 
over 2 million people were on ART by 2013.[6,7] Before 2008, it was 
standard policy in SA public sector hospitals to exclude HIV-positive 
patients from access to chronic dialysis. In 2008, this policy was 
reviewed. The SA renal and transplant societies jointly acknowledged 
that HIV-positive patients could not be excluded on the basis of their 
HIV status alone, and the guidelines were revised.[8]
Unfortunately the majority of patients with ESKD in the public 
healthcare system, including HIV-positive patients, have extremely 
limited access to chronic dialysis because of limited resources, whereas 
those with medical health insurance have unrestricted access.[9,10] There 
are no published data from SA on the outcomes of either of these 
groups of patients. This study was conducted to assess the outcomes of 
black HIV-positive individuals with ESKD on chronic haemodialysis, 
who have access to medical health insurance in SA.
Methods
This study was a national, retrospective cohort study. Approval 
was obtained from the Human Research Ethics Committee of the 
University of the Witwatersrand, approval No. M101120. National 
Renal Care (NRC) was the dialysis service provider for all the 
chronic haemodialysis centres that participated in the study. Adult 
HIV-positive patients over the age of 18 who had started chronic 
haemodialysis between 1 January 2006 and 31 October 2010 and 
had continued for at least 6 months were eligible for inclusion in the 
study. Informed consent was obtained from 48 of the HIV-positive 
patients (consent rate 24.5%). The date of the first dialysis session in 
the chronic dialysis unit was taken as commencement of the first year 
of dialysis, and each subsequent year on dialysis was defined from 
this point. Before commencement of the study, staff in the dialysis 
centres were trained by two of the authors on how to obtain informed 
consent in accordance with Good Clinical Practice guidelines.[11] 
Only those who had completed the training were eligible to obtain 
informed consent and were delegated by one of the authors to do so.
Both HIV-positive and HIV-negative patients were asked to participate 
in the study. They were supplied with a patient information leaflet, and 
written informed consent was obtained from those who agreed to 
participate. All patients who were HIV-positive and gave consent were 
included in the study. Participants with incorrectly completed consent 
forms were excluded. A group of HIV-negative patients who had given 
consent were then selected as matching controls in a 2:1 ratio. Dialysis 
prescriptions were individualised with respect to size of the dialysis 
membrane, blood flow rate and pump speed and reviewed as needed by 
the attending doctor, based upon the condition of the patient and his/her 
blood results. All patients received haemodialysis three times a week for 
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4 hours. Polysulfone haemodialysis membranes were used in all dialysis 
centres, and there was no re-use policy regarding membranes.
The following data were routinely collected on all patients: 
demographics (access to running water was defined as access within 
the proximity of the house/dwelling), medical history, blood tests 
performed at various intervals as standard of care, and medical 
information regarding acute/emergency hospital admissions. The 
following blood tests were done: corrected serum calcium (mmol/L), 
serum phosphate (mmol/L), haemoglobin (g/dL), serum ferritin 
(µg/L), serum albumin (g/L); and KT/V (K (urea clearance of 
dialyser (ml/min)) × T (dialysis time in minutes) ÷ V (volume (ml)), 
calculated as a measure of dialysis adequacy). Values for each year 
the patients were on the study were collected and an average was 
calculated per year of follow-up. Vascular access and transplant 
listing was defined at a single point in time, 31 October 2010. The 
prevalence of HIV infection (positive ELISA), chronic hepatitis 
B infection (hepatitis B surface antigen positivity for >6 months), 
hepatitis C infection (hepatitis C antibodies), and the total number of 
patients receiving chronic haemodialysis with NRC were defined at 
a single point in time, 31 October 2010. For the HIV-positive group, 
CD4 counts (cells/µl) were recorded per year of follow-up, and in 
the case of more than one value an annual average was calculated; 
the log HIV viral load (copies/ml) was determined using a single 
value as close as possible to the single point in time, 31 October 
2010. Medication regimens were obtained from patient records in the 
dialysis units, from the NRC database, and in some cases from the 
attending doctors’ patient files.
With regard to each hospital admission, the following data were 
collected (where appropriate): date of admission, date of discharge, 
and reason for admission (as determined by the admitting doctor); 
number of hospital admissions for the current year; date of infection 
and site of infection; date on which the dialysis access was created 
or removed; and how many previous dialysis access-related events 
the patient had. In the case of laboratory testing, the respective 
laboratories were accessed for information where necessary, e.g. for 
histology and tuberculosis (TB) culture results.
A positive diagnosis of TB was determined via either a clinical 
diagnosis with confirmatory laboratory results (histology, culture) or 
commencement of empiric anti-TB treatment based on the patient’s 
clinical presentation.
Hypertension was defined as a diagnosis of hypertension by the 
attending doctor or evidence from patient records that the patient was 
receiving antihypertensive treatment. Coronary artery disease was 
defined by the need for admission and included a diagnosis of either 
unstable angina or acute myocardial infarction from the attending 
doctor. Cerebrovascular events were defined by the need for admission 
and a diagnosis of a stroke (either thrombotic or haemorrhagic) or a 
reversible ischaemic neurological event as determined by the attending 
doctor. Average duration of follow-up was calculated by taking the total 
months on chronic dialysis of all patients and dividing this by the total 
number of patients. Incidence rate ratios were calculated by dividing 
the incidence in HIV-positive patients by the incidence in HIV-negative 
patients. ‘Patient-days’ were calculated by dividing the total number of 
days that patients were admitted during the period of follow-up divided 
by the number of patients in each group.
Statistical analysis was performed using the statistical package 
Stata 11 Data Analysis and Statistical Software. Descriptive statistical 
analysis was performed, as well as linear regression analysis 
comparing differences between the HIV-positive and HIV-negative 
groups, for each year on dialysis, over the 5-year study period.
Table 1. Demographics and comorbidity of the HIV-positive and HIV-negative patient groups
Parameter HIV-positive (N=48) HIV-negative (N=96) p-value
Follow-up (months), mean (95% CI for mean) 30.6 (25.4 - 35.9)  30.6 (26.8 - 34.5) 0.71
Age (years), mean (95% CI for mean) 43.4 (40.6 - 46.2) 45.1 (43.1 - 47.1) 0.82
Female gender, n (%) 20 (41.7) 39 (40.6) 0.84
Ethnicity, n (%)
Black 47 (97.9) 81 (84.4) 0.03
Mixed 1 (2.1) 11 (11.5)
Asian 4 (4.1) 0.15
Housing, n (%) 45 (93.8) 94 (97.9) 0.47
Members per household, mean (95% CI for mean) 3.9 (3.41 - 4.33) 4.2 (3.82 - 4.52) 0.53
Access to running water, n (%) 41 (85.4) 84 (87.5) 0.98
Employed, n (%) 35 (72.9) 61 (63.5) 0.50
Diabetes mellitus (prevalence), n (%) 9 (18.8) 18 (18.8) 0.60
Hypertension (prevalence), n (%) 33 (68.8) 82 (85.4) 0.09
Vascular access, n (%)
Arteriovenous fistula 30 (62.5) 58 (60.4) 0.32 (df = 2)
Arteriovenous graft 1 (2.1) 7 (7.3)
Tunnelled catheter 13 (27.1) 19 (19.8)
Unknown 4 (8.3) 12 (12.5)
On transplant wait list, n/N (%) 2/48 (4.2) 18/96 (18.8) 0.027
Continuous variables were compared using the unpaired t-test and categorical variables using the χ2 test. df = degrees of freedom.
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Results
A total of 2 010 patients received chronic 
haemodialysis nationally with NRC 
during the study period. Prevalence rates 
for infections were as follows: HIV 9.75% 
(196/2 010), hepatitis C 0.95% (19/2 010) 
and hepatitis B 1.59% (32/2 010). 
Comorbidity and demographic comparators 
between HIV-positive and HIV-negative 
patients are set out in Table 1.
The two groups were well matched, apart 
from a significantly higher proportion of 
black patients in the HIV-positive group. 
Significantly fewer HIV-positive than HIV-
negative patients were wait-listed for kidney 
transplantation. Incident disease while on 
the study is summarised in Table 2. The 
total number of patient days admitted, 
independent of cause for admission, was 
significantly higher for the HIV-positive 
group. Vascular access rates and access-
related admission rates with respect to 
arteriovenous fistula, arteriovenous graft 
and tunnelled catheter were similar in both 
groups, but the number of access-related 
infections that required hospital admission 
was statistically higher in the HIV-positive 
group. The incidence of treated TB infection 
was also significantly higher in the HIV-
positive group. In the HIV-positive group, 
log HIV viral suppression rates and mean 
CD4 counts per year of follow-up are set 
out in Table 3. The mean duration of ART 
was 30.1 months (n=31) (95% confidence 
interval (CI) for the mean 23.7 - 36.5). No 
data regarding ART exposure were available 
in 14/48 (29.2%) patients, and 3/48 (6.3%) 
were not on ART. In those documented 
on ART, 19/37 (51.4%) were not virally 
suppressed using log <2.0 as a cut-off.
Linear regression analysis showed that 
average haemoglobin levels (p<0.01) and 
serum albumin levels (p<0.05) were statistically 
significantly lower in the HIV-positive group 
for the duration of follow-up, although the 
average serum albumin level in the HIV-
positive group was nevertheless higher than 
30 g/L. There was no statistical difference 
between the groups for serum ferritin, calcium, 
phosphate and KT/V values (Table 4). Survival 
during follow-up in the two groups was 
comparable at 100% for HIV-positive and 99% 
for HIV-negative patients. One patient died 
and one received a kidney transplant.
Discussion
In this study, survival of medically insured 
black HIV-positive patients receiving 
chronic haemodialysis in SA was excellent, 
in spite of longer durations of hospital 
stay and higher infectious morbidity. 
Infectious morbidity was associated with 
higher hospital admission rates for vascular 
access-related infections, higher incidence 
rates for TB and inadequate HIV viral load 
suppression in those on ART.
Limitations of this study include 
the small sample size, inability to match 
the HIV-positive and negative groups 
perfectly with respect to ethnicity, and 
restriction of participants to a healthcare-
funded environment. These factors limit 
generalisation of the findings and do 
not accurately reflect the socioeconomic 
circumstances of the general population 
in SA. The consent rates for HIV-positive 
participants were unexpectedly low. It 
was thought that training staff to obtain 
consent would increase the recruitment 
rate, but these staff disclosed that they felt 
uncomfortable asking HIV-positive patients 
to participate and believed that a high 
patient load compromised their capacity for 
research-related activity.
Survival in the HIV-positive group was 
excellent. To date, the only other data 
available in SA on survival of black HIV-
positive patients receiving chronic dialysis are 
from a study conducted in the state-funded 
Helen Joseph Hospital in Johannesburg.
[12] In this study, 59 HIV-positive patients 
received chronic dialysis from 2001 to 2012, 
and although the demographics with respect 
to age, gender, ethnicity and mean follow-up 
were similar to those in the current study, 
mortality was much higher at 51% (30/59).
[12] Potential reasons for this discrepancy are 
probably multifactorial and may be related 
to a lower median CD4 count of 231 cells/µl 
and higher prevalences of co-infection with 
hepatitis B at 22% (13/59) and hepatitis C at 
5% (3/59), making the relative frequencies 14 
and five times more common, respectively, in 
the Helen Joseph study than in the current 
study. A further explanation for the discrepant 
survival was the choice of chronic renal 
replacement therapy – in our study only HIV-
positive patients on chronic haemodialysis 
were recruited, while in the Helen Joseph 
cohort chronic ambulatory peritoneal dialysis 
(CAPD) was the predominant mode of 
dialysis (63% (37/59)). Sixty-three per cent 
of deaths occurred in the CAPD group, the 
most common causes of death being fluid 
overload (38%) and peritonitis (31%), which 
are potentially preventable and easily treated. 
Table 2. Incident disease during follow-up in HIV-positive and HIV-negative patient groups
Parameter HIV-positive (N=48) HIV-negative (N=96) p-value
Cerebrovascular accident 0/123 person-years 4/238 person-years 0.15
Incidence rate 1.7:100
Coronary artery disease 0/123 person-years 7/238 person-years 0.06
Incidence rate 2.9:100
Tuberculosis 9/123 person-years 2/238 person-years 0.001
Incidence rate 7.3:100 0.8:100
Incidence rate ratio 8.7
Comparison done using Fisher’s exact test.
Table 3. HIV viral suppression and mean CD4 counts during follow-up
Log HIV viral load
HIV-positive patients on ART (N=37)
n (%)
<2.0 18 (48.6)
2.1 - 3.0 4 (10.8)
3.1 - 4.0 5 (13.5)
4.1 - 5.0 8 (21.6)
>5.0 2 (5.5)
Year of follow-up Mean CD4 count (cells/µl)* 95% CI for mean
1 (n=29) 293 207 - 378
2 (n=23) 335 246 - 423
3 (n=19) 306 202 - 409
4 (n=13) 309 200 - 416
5 (n=8) 320 134 - 505
*One-way analysis of variance p=0.27 (no significant difference between CD4 counts and year of follow-up).
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These deaths may reflect a combination of 
lower socioeconomic status and poor access 
to healthcare facilities when acutely ill.
Our survival rate for HIV-positive patients 
on chronic haemodialysis is better than 
international figures. In the international 
literature, survival of HIV-positive patients 
receiving chronic haemodialysis in various 
cohorts in the USA ranged from 74% at 1 
year to 30% at 2 years.[2,4] In Europe, 1- and 
2-year survival rates were 93.8% and 89.4%, 
respectively, with the strongest predictors 
of survival being CD4 counts >200 cells/µl 
and serum albumin >30 g/L,[2,5] which are 
comparable to the CD4 counts and serum 
albumin levels in the patients in our study.
Our HIV-positive patients did have in creased 
rates of infection. TB was the most common 
opportunistic pathogen in the HIV-positive 
group, and this was also seen in the study at 
Helen Joseph Hospital.[12] There are very few 
data regarding susceptibility to TB in HIV-
positive dialysis patients.[13,14] HIV status 
alone, independent of chronic dialysis, can 
explain the increased predilection to inci-
dent TB and has been well described.[15] 
This study confirmed a much higher relative 
risk of incident TB in HIV-positive patients 
(incidence rate ratio 8.7), even with relatively 
well-preserved CD4 counts and good socio-
economic circumstances.
HIV-positive patients were admitted 
more frequently for vascular access-related 
infections than HIV-negative patients. There 
are conflicting reports on the impact of HIV 
on vascular access infection rates in HIV.
[16] Some studies have shown no differ ences 
between HIV-positive and HIV-negative 
patients, while others have shown that 
vascular access-related infections were more 
prevalent in those with lower CD4 counts, 
hepatitis B antigenaemia and injecting drug 
use.[17,18] The results of our study are different 
to these findings, as there were increased rates 
of admission for access-related infection in 
the HIV-positive group in spite of relatively 
well-preserved CD4 counts and low levels 
of hepatitis B antigenaemia. The impact of 
injecting drug use in our setting is unknown.
The USA has the third highest prevalence 
of injecting drug use in the world (0.96%), 
and an associated HIV prevalence among 
injectors of 16%.[19] A study in 2012 showed 
that there were 67  000 injecting drug users 
in SA. This translates to a population 
prevalence of 0.13%, which is approximately 
seven times less frequent than that in the 
USA. The HIV prevalence in this group 
was 19.4%.[20,21] There are no data from SA 
on injecting drug use in chronic dialysis 
populations, but based on the national 
prevalence rates it is possible to infer that the 
prevalence in dialysis units is low, and the 
impact of injecting drug use on outcomes in 
this patient group would be minimal.
An unexpected finding was the treatment 
response in the HIV-positive patients on 
ART. The HIV viral load was incompletely 
suppressed in 51% of participants on 
treatment. Regular testing of CD4 counts 
and HIV viral loads after initiation of ART 
was not standardised and data were scanty. 
Poor HIV viral suppression with chronic 
dialysis has been documented, with rates 
of complete HIV suppression ranging 
from 44% to 88%. This has been correlated 
with higher mortality.[12,22-24] Reasons for 
incomplete HIV viral suppression have 
been ascribed to inexperience with HIV 
treatment and poor prescribing practices 
by nephrologists, with both under- and 
over-prescription of ART, and infrequent 
consultation and follow-up with an infectious 
diseases specialist.[24] These factors must be 
Table 4. Summary data for blood indices on all patients
Parameter/year of follow-up
HIV-negative
mean (SD)
HIV-positive
mean (SD) p-value
KT/V
1 1.23 (0.27) 1.21 (0.29) 0.079
2 1.33 (0.29) 1.16 (0.26)
3 1.21 (0.23) 1.16 (0.25)
4 1.31 (0.42) 1.22 (0.35)
5 1.33 (0.31) 1.27 (0.21)
Serum ferritin (µg/L)
1 586 (711) 699 (917) 0.497
2 667 (841) 644 (723)
3 700 (1 063) 748 (660)
4 962 (1 499) 931 (1 068)
5 769 (1 065) 946 (928)
Serum haemoglobin (g/dL)
1 10.3 (14) 9.4 (12) <0.001
2 11.0 (16) 10.3 (15)
3 11.0 (26) 10.3 (14)
4 10.3 (29) 10.4 (13)
5 10.6 (25) 9.5 (15)
Serum albumin (g/L) 0.015
1 34.8 (4.7) 32.5 (5.7)
2 35.8 (4.1) 33.6 (5.8)
3 36.4 (4.1) 35.1 (6.1)
4 36.6 (4.0) 35.2 (6.5)
5 36.3 (4.2) 35.4 (5.4)
Serum calcium (mmol/L) 0.462
1 2.2 (0.19) 2.26 (0.25)
2 2.18 (0.25) 2.19 (0.22)
3 2.21 (0.20) 2.16 (0.21)
4 2.16 (0.29) 2.12 (0.20)
5 2.21 (0.25) 2.21 (0.15)
Serum phosphate (mmol/L) 0.98
1 1.58 (0.47) 1.55 (0.47)
2 1.52 (0.40) 1.60 (0.58)
3 1.64 (0.41) 1.64 (0.54)
4 1.59 (0.39) 1.52 (0.52)
5 3.12 (6.8) 1.56 (0.40)
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considered as possible explanations in this study, as many nephrolo-
gists initiate and continue ART without input from an infectious 
diseases specialist in the medically insured setting. The impact 
of suboptimal practice may adversely affect the outcomes of this 
group of HIV patients, not only with respect to mortality but also 
eligibility for kidney transplantation. Although poorer outcomes 
were not reflected in this study, the effect may have been masked by 
small numbers. These preliminary findings deserve further scientific 
exploration in future studies and in the development of clinical 
practice guidelines for nephrologists who care for HIV patients in SA.
Conclusion
Black HIV-positive patients on chronic haemodialysis in a 
healthcare-funded environment in SA had excellent survival rates 
that were comparable with those in their HIV-negative counterparts 
despite suboptimal HIV viral suppression, lower serum albumin 
and haemoglobin levels, and a higher incidence of TB and vascular 
access-related infections that required hospital admission.
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